Skip to main content

Table 2 Three and 5-year data in all, operable, and inoperable patients

From: Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study

 

All patients (n = 71)

Operable patients (n = 24)

Inoperable patients (n = 47)

p-valuea

OS (%) at 3/5 years

73/65

71/66

74/65

0.78

PFS (%) at 3/5 years

64/55

58/49

68/60

0.61

Cumulative incidence of LR (%) at 3/5 years

12/15

17/21

9/12

0.34

  1. OS Overall survival, PFS Progression-free survival, LR Local recurrence
  2. aDifference between operable and inoperable patients
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us